FDA Brief

Warning letters Drugs

FDA warning letter to

Deqing Jiarou Daily Chemical Co., Ltd.

High riskIssued Mar 18, 2024Posted Mar 26, 2024Center for Drug Evaluation and Research | CDER

Deqing Jiarou failed current good manufacturing practice (CGMP) for OTC hand sanitizer, including no methanol testing of ethanol.

What happened

FDA reviewed records the company submitted after FDA's September 12, 2022 request under section 704(a)(4) of the FD&C Act. FDA said the records showed significant current good manufacturing practice (CGMP) violations for OTC drug products, including hand sanitizer: no demonstration of incoming component identity testing, no testing of ethanol for methanol, no adequate finished-batch release testing, a four-week stability report, and ineffective quality unit oversight.

What FDA found

  1. The firm failed to conduct at least one identity test for each incoming drug component and did not show that it tests ethanol for methanol.

    21 CFR 211.84(d)(1)
  2. The firm failed to perform appropriate laboratory testing of each finished batch for identity and strength before release, and its certificates of analysis lacked active ingredient assay and impurity testing.

    21 CFR 211.165(a)
  3. The firm failed to establish and follow an adequate written stability program, providing only four weeks of stability data and no chemical or microbiological stability testing data.

    21 CFR 211.166(a)
  4. The firm failed to establish an adequate quality control unit with authority to approve or reject components, containers, closures, in-process materials, packaging, labeling, and drug products.

    21 CFR 211.22(a)

What FDA wants

FDA asks the company to respond in writing within 15 working days describing corrections and steps to prevent recurrence, and to correct violations promptly. If the firm intends to resume U.S. drug manufacturing, FDA recommends a qualified CGMP consultant.

Who should pay attention

  • brands that buy OTC hand sanitizer from this contract manufacturer
  • companies sourcing ethanol or drug components from this supplier
  • U.S. importers and distributors of OTC drug products

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk